Comparison · NCT05343455-b9bcac80
DFD-29 vs Placebo: Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. DFD-29 vs Placebo: Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo. Trial comparisons, record NCT05343455-b9bcac80. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05343455-b9bcac80
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.602 | 0.513 | 0.684 | wilson | |
| Risk in group 2 | 0.268 | 0.184 | 0.373 | wilson | |
| Risk difference, group 1 minus group 2 | 0.333 | 0.196 | 0.451 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.24 | 1.53 | 3.3 | log | |
| Odds ratio, group 1 over group 2 | 4.12 | 2.24 | 7.56 | log | |
| Number needed to treat, for one more participant with the outcome on DFD-29 than on Placebo | 3 | 2.22 | 5.09 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | DFD-29 | DFD-29 (40 mg) extended release capsules~DFD-29: DFD-29 (40 mg) extended release capsules | 74 | 123 | OG000 |
| Group 2 | Placebo | Placebo capsules matching DFD-29~Placebo: Placebo capsules | 22 | 82 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo.
- Description
Proportion of subjects with IGA (modified scale without erythema) 'treatment success' - Grade 0 or 1 at Week 16 with at least 2 grade reduction from Baseline to Week 16, in the DFD-29 group compared to Placebo.~The modified IGA scale is a 5-point scale from Grade 0 to Grade 4, wherein Grade 0 is Clear, Grade 1 is Near Clear, Grade 2 is Mild, Grade 3 is Moderate and Grade 4 is Severe Rosacea. A lowering of the score with treatment indicates an improvement in the disease condition and a beneficial outcome.
- Time frame
- Baseline to Week 16
- Population
- Intent-to-Treat Subjects
Source ClinicalTrials.gov
Trial
- Title
- A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
- NCT number
- NCT05343455
- Phases
- PHASE3
- Conditions
- Papulopustular Rosacea
- Interventions
- DFD-29, Doxycycline, Placebo
- Lead sponsor
- Journey Medical Corporation
- Results first posted
- 2024-12-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05343455?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05343455-b9bcac80